Literature DB >> 7094252

The cardiac effects of d- and l-disopyramide in normal subjects: a noninvasive study.

C Pollick, K M Giacomini, T F Blaschke, W L Nelson, K Turner-Tamiyasu, V Briskin, R L Popp.   

Abstract

Commercially available disopyramide is a racemic mixture of equal parts of dextrorotatory (d-) and levorotatory (l-) optical isomers. We studied the cardiac effects of i.v. administration of each isomer and the racemic mixture (dl-) in six normal males by digitized echocardiography, systolic time intervals and ECG. Both isomers and the racemic mixture produced equally marked dose-dependent negative inotropic effects (28.1 +/- 11.8% mean maximal reduction in fractional shortening of left ventricular dimension) and diastolic effects (28.6 +/- 24.1% mean maximal reduction in peak left ventricular filling rate). However, only the d-isomer prolonged QTc duration (by 13.6 +/- 5.2% at maximum, p less than 0.001 vs l-isomer). We conclude that disopyramide, in the doses used, produces marked adverse effects on left ventricle systolic and diastolic function in normal subjects independent of optical rotation. The production of these effects by the l-isomer without affecting QTc duration suggests different subcellular mechanisms for the myocardial depressant effects and some of the electrophysiologic effects of disopyramide.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7094252     DOI: 10.1161/01.cir.66.2.447

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  14 in total

1.  Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide.

Authors:  K M Giacomini; T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of disopyramide.

Authors:  L A Siddoway; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

3.  Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man.

Authors:  J Hasselström; M Enquist; J Hermansson; R Dahlqvist
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  [Hemodynamic effects of disopyramide on postischemic and normal myocardium].

Authors:  H M Hoffmeister; H P Hörmann; M Beyer; L Seipel
Journal:  Klin Wochenschr       Date:  1990-12-04

Review 5.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

Review 6.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

7.  Effects of the enantiomers of disopyramide and its major metabolite on the electrophysiological characteristics of the guinea-pig papillary muscle.

Authors:  F Vanhoutte; J Vereecke; E Carmeliet; N Verbeke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-12       Impact factor: 3.000

8.  Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.

Authors:  J J Lima; D B Haughey; C V Leier
Journal:  J Pharmacokinet Biopharm       Date:  1984-06

9.  Haemodynamic effects and kinetics of concomitant intravenous disopyramide and atenolol in patients with ischaemic heart disease.

Authors:  J Bonde; L E Pedersen; H R Angelo; J Trap-Jensen; T L Svendsen; J P Kampmann
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants.

Authors:  T Nakagawa; S Kishino; S Itoh; M Sugawara; K Miyazaki
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.